An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

Summary

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Timeline

Start

2016-09-02

Primary completion

2017-04-10

Completion

2017-10-16

Drugs

Indications